Physician profile
Nicole E Jackson
NPI 1578084927
$3,247.68
in general payments reported to CMS, 2019-2025
29 companies · $774 in 2025
The $774 reported for 2025 was more than what 81% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $18.25 · 2021: $425 · 2022: $293 · 2023: $587 · 2024: $1,152 · 2025: $774.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,380 · Education: $132.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,379.72 |
| Education | $132.26 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $573.15 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $358.69 | 2021-2025 | |
| Lilly USA, LLC | $320.36 | 2021-2025 | Zepbound, Mounjaro |
| Boehringer Ingelheim Pharmaceuticals, INC. | $281.84 | 2021-2025 | Jardiance |
| Ardelyx, INC. | $194.78 | 2024-2025 | Ibsrela |
| Exact Sciences Corporation | $166.13 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Astrazeneca Pharmaceuticals LP | $161.76 | 2021-2025 | Breztri, Airsupra, Lokelma |
| Astellas Pharma US INC | $139.87 | 2024-2025 | Veozah |
| Grifols USA, LLC | $127.48 | 2024-2025 | Prolastin-C Liquid |
| Pfizer INC. | $109.23 | 2019-2024 | |
| Phathom Pharmaceuticals, INC. | $98.52 | 2024-2025 | Voquezna |
| Amgen INC. | $76.46 | 2022-2025 | Repatha, Otezla, Evenity |
| Boston Scientific Corporation | $72.92 | 2024 | Wavewriter Alpha Prime 16 |
| Mylan Specialty L.P. | $67.23 | 2022-2023 | Yupelri |
| Idorsia Pharmaceuticals US INC | $57.00 | 2023-2024 | Quviviq |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Corium, LLC | $53.46 | 2023 | Adlarity |
| Bayer Healthcare Pharmaceuticals INC. | $53.25 | 2022-2024 | |
| Janssen Pharmaceuticals, INC | $47.81 | 2021 | |
| Daiichi Sankyo INC. | $47.19 | 2021-2023 | Injectafer |
| Shield Therapeutics INC | $44.96 | 2023-2025 | Accrufer |
| Sumitomo Pharma America, INC. | $38.45 | 2025 | Gemtesa |
| Inspire Medical Systems, INC. | $27.62 | 2025 | Inspire |
| Edwards Lifesciences Corporation | $27.50 | 2023 | Sapien 3 Ultra Resilia |
| Actelion Pharmaceuticals US, INC. | $20.50 | 2024 | Opsumit, Uptravi |
| Otsuka America Pharmaceutical, INC. | $19.53 | 2025 | Rexulti |
| Agios Pharmaceuticals, INC. | $18.23 | 2025 | Pyrukynd |
| Esperion Therapeutics, INC. | $17.57 | 2024 | Nexletol |
| Currax Pharmaceuticals LLC | $13.89 | 2024 | Contrave |
| Glaxosmithkline, LLC. | $12.30 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nicole Jackson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.